辅助一种COVID-19疫苗以诱导保护性免疫力
Prabhu S Arunachalam1, Alexandra C Walls2, Nadia Golden3
1Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford University, Stanford, CA, USA.
Nature
|April 19, 2021
概括
一种新型子单位疫苗RBD-NP在中显示出强大的SARS-CoV-2保护作用. 这种疫苗与特定的辅助剂相结合,诱导了持久的中和抗体反应,并保护了感染.
科学领域:
- 免疫学
- 疫苗学
- 病毒学
背景情况:
- 开发有效的COVID-19疫苗是全球卫生优先事项.
- 亚单位疫苗为SARS-CoV-2免疫提供了一个有希望的方法.
研究的目的:
- 评估受体结合域纳米粒子 (RBD-NP) 亚单元疫苗对SARS-CoV-2的疗效.
- 评估不同辅助剂对疫苗诱导的免疫反应和保护的影响.
主要方法:
- 用五种不同的辅助剂配制的RBD-NP免疫接种.
- 测量了幽默和细胞免疫反应.
- 在各种组织中评估了对SARS-CoV-2挑战的保护.
主要成果:
- 与AS03,CpG1018-alum,AS37或alum一起的RBD-NP诱导了显著的中和抗体和CD4 T细胞反应.
- 接种疫苗可以防止呼吸道感染SARS-CoV-2.
- RBD-NP-AS03表现出长达180天的中和抗体反应,并有效地对B.1.1.7变种进行了交叉中和.
- 对B.1.351变种观察到降低的中和,在AS03和AS37辅助剂之间观察到差异.
结论:
- 辅助RBD-NP疫苗有效诱导对SARS-CoV-2的保护性免疫力.
- 辅助剂的选择会影响中和抗体反应的范围.
- 这些发现支持RBD-NP疫苗正在进行的临床开发.
更多相关视频
10:58Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
Published on: August 21, 2019
7.8K
09:03Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development
Published on: June 19, 2018
8.9K
相关概念视频
Vaccinations
48.8K
Overview
48.8K
Cancer Vaccines
603
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
603
Active versus Passive Immunity
9.2K
Immunity, along with the ability to limit pathogen growth to prevent significant body tissue damage, can be gained either by (1) actively developing an immune response within the individual after exposure to a pathogen or after getting vaccinated or (2) passively transferring immune components from an immune individual to one who is nonimmune. Both these forms of immunity can be found naturally and in medical practices.
Active Immunity
Active immunity refers to the resistance one develops...
Active Immunity
Active immunity refers to the resistance one develops...
9.2K
Immune Response Against Viral Pathogens
1.2K
The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
1.2K
Antigens Involved in Adaptive Immunity
880
An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and...
Complete Antigens
Complete antigens possess both immunogenicity and...
880
Development of Immunocompetence
561
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
561
